<DOC>
	<DOCNO>NCT00808210</DOCNO>
	<brief_summary>This Phase II , randomize , active-controlled , double-blind , double-dummy , parallel-group , multicenter study United States enrol patient active RA . The study enroll approximately 290 patient approximately 130 site .</brief_summary>
	<brief_title>A Study Evaluate Ocrelizumab Combination With Methotrexate Compared With Infliximab Plus Methotrexate Patients With Active Rheumatoid Arthritis Currently Responding Inadequately Etanercept Adalimumab</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Age &gt; = 18 year Current treatment RA outpatient basis Active disease Currently receive 50 mg etanercept subcutaneously ( SC ) every week 40 mg adalimumab SC every week . Considered Investigator primary nonresponder first antiTNFÎ± treatment efficacy reason Rheumatic autoimmune disease RA , significant systemic involvement secondary RA History , current , inflammatory joint disease RA ( e.g. , gout , reactive arthritis , psoriatic arthritis , seronegative spondyloarthropathy , Lyme disease ) systemic autoimmune disorder ( e.g. , systemic lupus erythematosus , inflammatory bowel disease , scleroderma , inflammatory myopathy , mixed connective tissue disease overlap syndrome ) Previous treatment biologic therapy RA ( include investigational product exception etanercept adalimumab Treatment one prior antiTNFÎ± therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>RA</keyword>
	<keyword>Arthritis</keyword>
</DOC>